CIML NK cells / Washington University School of Medicine in St. Louis - LARVOL DELTA

Cytokine Induced Memory-like NK Cell Adoptive Therapy for Relapsed AML After Allogeneic Hematopoietic Cell Transplant (clinicaltrials.gov) - P1/2 | N=62 | Completed | Sponsor: Washington University School of Medicine | Recruiting ➔ Completed | N=110 ➔ 62 | Trial completion date: Oct 2028 ➔ Jun 2025 | Trial primary completion date: Oct 2028 ➔ Jun 2025

Enrollment change • Trial completion • Trial completion date • Trial primary completion date • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Neutropenia • Oncology • Transplantation

Cytokine Induced Memory-like NK Cell Adoptive Therapy After Haploidentical Donor Hematopoietic Cell Transplantation (clinicaltrials.gov) - P2 | N=60 | Active, not recruiting | Sponsor: Washington University School of Medicine | Recruiting ➔ Active, not recruiting | Trial completion date: Jan 2027 ➔ Sep 2026 | Trial primary completion date: Jan 2027 ➔ Sep 2026

Enrollment closed • Trial completion date • Trial primary completion date • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Oncology • Transplantation

Cytokine Induced Memory-like NK Cell Adoptive Therapy After Haploidentical Donor Hematopoietic Cell Transplantation (clinicaltrials.gov) - P2 | N=60 | Recruiting | Sponsor: Washington University School of Medicine | Trial completion date: Jul 2026 ➔ Jan 2027 | Trial primary completion date: Jul 2026 ➔ Jan 2027

Trial completion date • Trial primary completion date • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Oncology • Transplantation

Cytokine Induced Memory-like NK Cell Adoptive Therapy for Relapsed AML After Allogeneic Hematopoietic Cell Transplant (clinicaltrials.gov) - P1/2 | N=110 | Recruiting | Sponsor: Washington University School of Medicine | Active, not recruiting ➔ Recruiting | N=62 ➔ 110 | Trial completion date: Nov 2025 ➔ Oct 2028 | Trial primary completion date: Nov 2025 ➔ Oct 2028

Enrollment change • Enrollment open • Trial completion date • Trial primary completion date • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Neutropenia • Oncology • Transplantation

Cytokine Induced Memory-like NK Cell Adoptive Therapy for Relapsed AML After Allogeneic Hematopoietic Cell Transplant (clinicaltrials.gov) - P1/2 | N=62 | Active, not recruiting | Sponsor: Washington University School of Medicine | Recruiting ➔ Active, not recruiting | N=110 ➔ 62 | Trial completion date: Oct 2028 ➔ Nov 2025 | Trial primary completion date: Oct 2028 ➔ Nov 2025

Enrollment change • Enrollment closed • Trial completion date • Trial primary completion date • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Neutropenia • Oncology • Transplantation

Cytokine Induced Memory-like NK Cell Adoptive Therapy After Haploidentical Donor Hematopoietic Cell Transplantation (clinicaltrials.gov) - P2 | N=60 | Recruiting | Sponsor: Washington University School of Medicine | Trial completion date: Jan 2026 ➔ Jul 2026 | Trial primary completion date: Jan 2026 ➔ Jul 2026

Trial completion date • Trial primary completion date • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Oncology • Transplantation

A "Prime and Expand" strategy using the multifunctional fusion proteins to generate memory-like NK cells for cell therapy. (PubMed, Cancer Immunol Immunother) - "The resulting "Prime and Expand" ML NK cells exhibited elevated metabolic capacity, stable epigenetic IFNG promoter demethylation, enhanced antitumor activity in vitro and in vivo, and superior persistence in NSG mice. Thus, the "Prime and Expand" strategy represents a simple feeder cell-free approach to streamline manufacturing of clinical-grade ML NK cells to support multidose and off-the-shelf ACT."

Journal • Hematological Disorders • Hematological Malignancies • Oncology • IFNG • IL12A • IL15 • IL18 • IL21 • IL7

Cytokine Induced Memory-like NK Cell Adoptive Therapy for Relapsed AML After Allogeneic Hematopoietic Cell Transplant (clinicaltrials.gov) - P1/2 | N=110 | Recruiting | Sponsor: Washington University School of Medicine | Trial completion date: Oct 2026 ➔ Oct 2028 | Trial primary completion date: Oct 2026 ➔ Oct 2028

Trial completion date • Trial primary completion date • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Neutropenia • Oncology • Transplantation

Cytokine Induced Memory-like NK Cell Adoptive Therapy After Haploidentical Donor Hematopoietic Cell Transplantation (clinicaltrials.gov) - P2 | N=60 | Recruiting | Sponsor: Washington University School of Medicine | Trial completion date: Jan 2025 ➔ Jan 2026 | Trial primary completion date: Jan 2025 ➔ Jan 2026

Trial completion date • Trial primary completion date • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Oncology • Transplantation

Cytokine-induced Memory-like NK Cells in Combination With Chemotherapy in Pediatric Patents With Refractory or Relapsed AML (clinicaltrials.gov) - P2 | N=0 | Withdrawn | Sponsor: Washington University School of Medicine | N=48 ➔ 0 | Not yet recruiting ➔ Withdrawn

Combination therapy • Enrollment change • Trial withdrawal • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Oncology • Pediatrics

Cytokine-induced Memory-like NK Cells in Combination With Chemotherapy in Pediatric Patents With Refractory or Relapsed AML (clinicaltrials.gov) - P2 | N=48 | Not yet recruiting | Sponsor: Washington University School of Medicine | Trial completion date: Jan 2028 ➔ Jul 2028 | Trial primary completion date: Mar 2026 ➔ Sep 2026

Combination therapy • Trial completion date • Trial primary completion date • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Oncology • Pediatrics

Cytokine-induced Memory-like NK Cells in Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) (clinicaltrials.gov) - P1/2 | N=89 | Terminated | Sponsor: Washington University School of Medicine | Trial completion date: Dec 2024 ➔ Apr 2022 | Active, not recruiting ➔ Terminated; Insufficient funding/staff

Trial completion date • Trial termination • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Myelodysplastic Syndrome • Oncology

Putative Predictors of Response to WU-NK-101, an Allogeneic, Enhanced Memory (ML) Natural Killer (NK) Cell Therapy Product, for Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) (ASH 2022) - "Cytokine-induced memory-like (CIML) NK cells are more potent for anti-tumor responses than conventional NK (cNK) cells, are well tolerated, and active in patients with R/R AML (NCT#01898793) with complete response (CR)/CR with partial/incomplete hematologic recovery rate of 47% and a median DOR of 9.4 months after a single infusion (Berrien-Elliott, et al...Compared to cNK cells, WU-NK-101 had enhanced trafficking to the BM, anti-tumor activity, and a metabolic profile consistent with aerobic glycolysis, potentially contributing to mitigating TME adversity. Due to their resilience to an immunosuppressive TME, WU-NK-101 cells may represent an effective treatment modality for R/R AML; a phase 1 study of WU-NK-101 in R/R AML is in development (NCT #05470140)."

Acute Myelogenous Leukemia • Hematological Disorders • Hematological Malignancies • Leukemia • Oncology • CD69 • CD7 • FUT4 • GZMB • IFNG • IL1RN • IL2 • IL2RA • IL6R • NLRP3

Cytokine Induced Memory-like NK Cell Adoptive Therapy After Haploidentical Donor Hematopoietic Cell Transplantation (clinicaltrials.gov) - P2 | N=60 | Recruiting | Sponsor: Washington University School of Medicine | Trial completion date: Jan 2024 ➔ Jan 2025 | Trial primary completion date: Jan 2024 ➔ Jan 2025

Trial completion date • Trial primary completion date • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Oncology • Transplantation

Cytokine-induced Memory-like NK Cells in Combination With Chemotherapy in Pediatric Patents With Refractory or Relapsed AML (clinicaltrials.gov) - P2 | N=48 | Not yet recruiting | Sponsor: Washington University School of Medicine | Trial completion date: Jun 2027 ➔ Jan 2028 | Trial primary completion date: Aug 2025 ➔ Mar 2026

Combination therapy • Trial completion date • Trial primary completion date • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Oncology • Pediatrics